Weight-loss drug Ozempic receives CDSCO approval for India launch

The race for a share of India’s growing obesity market is set to intensify with the Central Drugs Standard Control Organisation (CDSCO) giving Danish drugmaker Novo Nordisk approval for its blockbuster diabetes drug Ozempic.

 

Approval for the injectable semaglutide-based solution was given on September 26, according to the CDSCO’s website. While no timeline has been given, people in the know told Business Standard that the drug was expected to be launched soon.

 

Experts say Ozempic’s entry is expected to give a boost to the antiobesity market, estimated to be ₹752 crore. Of this market, semaglutide accounts for ₹426 crore.  

 

Vikrant